News

The AIDS Clinical Trials Group (ACTG) is launching a phase 3 trial to evaluate the safety and efficacy of tecovirimat to treat monkeypox in vulnerable populations.

The vaccine is available in adults 18 years and older.

The Lancet Commission called for global cooperation to end the continued spread of COVID-19 and effectively prevent future pandemics.

Why do some children develop polio-like paralysis after contracting enterovirus? Here’s everything we know about the rare but increasing reports of acute flaccid myelitis.

There are a number of programs designed to help lower rates of infection and transmission amongst this industry's workforce in South Africa.

The declaration not only puts the country on a list of countries circulating the viruses, but it also means polio continues to be transmitted in Rockland County, NY, and surrounding areas.

COVID-19 viral load rebound occurred in 2.3% of nirmatrelvir–ritonavir (Paxlovid) recipients and in 1.7% of placebo recipients.

A meta-analysis study shows having the comorbidity presents significant health risks for this patient population.

The brand’s specific meat product may contain E coli O157:H7.

Adenovirus was determined to have caused most cases of hepatitis of unknown origin in children.

Investigators surmise a natural bat exposure within certain areas of the world may correspond with lower COVID-19 incidence rates.

Injected COVID-19 mRNA vaccines alone were ineffective at producing mucosal antibody responses, according to a recent study that suggested seeking new strategies such as intranasal vaccines.

Investigators noted 2 distinct phases of HIV virus levels, meaning any infected cells that survive treatment can become latent, only to reignite HIV infection after antiretroviral therapy is stopped.

The same 5-year survival rates with kidney transplants from HCV positive and negative donors supports revising HCV "penalty" in ranking donors.

Texas judge Reed O’Connor ruled that requiring employers to cover the medical expense of HIV PrEP is a violation of religious freedom.

COVID-19 disease severity was mild in individuals in Qatar infected with the Omicron BA.1 and BA.2 sublineages with vaccination and booster doses reducing risks even further, a new study showed.

WHO and CDC have laid out some ambitious goals for the treatment of hepatitis C, and HCV co-discoverer and vaccine developer Michael Houghton, PhD, offers some insights and commentary on whether he feels it is realistic to consider the eradication of this stubborn and subtle virus.

The Liver Health Initiative’s Thelma King Thiel, and HCV co-discoverer and vaccine developer Michael Houghton, PhD, are a “Dynamic Duo” that are working together to bring about an end to this virus.

In the latest column from the Society of Infectious Diseases Pharmacists (SIDP), here is a discussion on the use of rifampin as an adjunctive antibiotic treatment for patients with diabetic foot osteomyelitis.

Nobel Prize Laureate Michael Houghton, PhD, discusses the arduous journey to find the virus and a subsequent investigational vaccine designed to prevent hepatitis C (HCV).

Injection drug users who received accessible care treatment at a syringe service program were almost 3 times as likely to complete their hepatitis C treatment than people who received usual care.

When physicians were told that a case was likely viral they were less likely to prescribe antibiotics, a new study shows.

"Real-world" population study finds the oral antivirals authorized for non-hospitalized COVID-19 patients can benefit when started in the hospital.

Catch up on all the important news and clinical care topics you may have missed this week.

Reviewers weigh evidence for the benefit of oral PrEP protection from HIV with risk of exacerbating hepatitis B.

The federal agency's recommendation for both the Moderna and the Pfizer-BioNTech updated bivalent vaccines allows people to get the booster dose this fall.

Taking into account the first PrEP pill was FDA approved in 2012, a clinician reflects on its significance and where the shortcomings of education and utility of it needs to be fortified.

A new report underscores a persistent problem of patients not receiving antivirals despite their high curative rate.

This Emergency Use Authorization for the Moderna and Pfizer-BioNTech vaccines brings them both one step closer for people to become eligible for these boosters.